Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy

Daniel J. LandsburgAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USACorrespondence[email protected]

Sunita D. NastaAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

James N. GersonAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Jakub SvobodaAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Elise A. ChongAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Stephen J. SchusterAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Stefan K. BartaAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Kyle W. RobinsonAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

Mitchell E. HughesAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA

show all

Citations (0)

Keep up to date with the latest research on this topic with citation updates for this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Time-to-response for patients with relapsed/refractory diffuse large B cell and high grade B cell lymphoma treated with polatuzumab-based therapy

Citations (0)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date